Recent studies highlight that Δ133p53 and Δ160p53 short isoforms may inactivate full-length p53 by tetramerization and fast aggregation, potentially exerting a “dominant-negative effect” or promoting cancer aggressiveness by “gain of function” mechanism [48]. The gene discussed is TP53; the disease is cancer.